NCT01887197 is a Phase 1 clinical trial of Absorptive clearance scan in Cystic Fibrosis, sponsored by Tim Corcoran.

Who is sponsoring NCT01887197?

NCT01887197 is sponsored by Tim Corcoran.

What drugs are being tested in NCT01887197?

Interventions in NCT01887197: Absorptive clearance scan, inhaled hypertonic saline (7%), mannitol inhalation powder.

What condition does NCT01887197 study?

NCT01887197 studies Cystic Fibrosis.

Is NCT01887197 still recruiting?

NCT01887197 is currently completed. Last updated 2 November 2018.

Last reviewed 2018-11-02 · How we verify

NCT01887197

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeatability and Response Study of Absorptive Clearance Scans

Completed Phase 1 Last updated 2 November 2018

What this trial tests

Phase 1 trial testing Absorptive clearance scan in Cystic Fibrosis in 24 participants. Completed in 1 May 2018.

Timeline

1 June 2013

Primary endpoint
1 December 2017

1 May 2018

Quick facts

Lead sponsor	Tim Corcoran
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	24
Start date	1 June 2013
Primary completion	1 December 2017
Estimated completion	1 May 2018
Sites	1 location across United States

Drugs / interventions tested

Absorptive clearance scan
inhaled hypertonic saline (7%) — full drug profile →
mannitol inhalation powder — full drug profile →

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Tim Corcoran — full company profile →

Who can join

18 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

absorptive clearance variability
Time frame: 30 days
The difference in absorptive clearance measured on two different study days in the same subjects as an indicator of measurement variability
absorptive clearance response
Time frame: 14 day
The change in absorptive clearance demonstrated in response to therapy when compared to baseline

Sponsor's own description

The investigators are developing a new nuclear medicine imaging technique for measuring liquid absorption in the airways that can be applied to screen new medications being developed to treat cystic fibrosis (CF). The investigators believe that the absorption of the small molecule radiopharmaceutical Indium 111 diethylene triamine pentaacetic acid (In-DTPA) will indicate changes in liquid absorption in the airways and demonstrate whether new CF medications will be effective. In this study the investigators will determine whether the imaging technique will demonstrate similar results when it is repeated on different days. They will also determine how their results change when subjects utilize several common CF medications.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
Locke LW, Myerburg MM, Weiner DJ, Markovetz MR, et al · · 2016 · cited 22× · PMID 27009167 · DOI 10.1183/13993003.01880-2015
Multiprobe Nuclear Imaging of the Cystic Fibrosis Lung as a Biomarker of Therapeutic Effect.
Corcoran TE, Huber AS, Myerburg MM, Weiner DJ, et al · · 2019 · cited 4× · PMID 30969149 · DOI 10.1089/jamp.2018.1491

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01887197 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tim Corcoran
Last refreshed: 2 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01887197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing